Karius Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
199
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$100M
- Investors
-
20
Karius General Information
Description
Operator of a clinical laboratory testing center intended to generate genomic insights for infectious diseases. The company's tests map each patient's microbial landscape from a single blood draw and develop molecular biology and data analysis tools that use deep sequencing to detect minuscule traces of microbial deoxyribonucleic acid directly from blood, enabling physicians to make rapid life-saving treatment decisions in a hassle-free manner.
Contact Information
Website
www.kariusdx.comCorporate Office
- 975 Island Drive
- Suite 101
- Redwood City, CA 94065
- United States
Corporate Office
- 975 Island Drive
- Suite 101
- Redwood City, CA 94065
- United States
Karius Timeline
Karius Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series C) | 02-May-2024 | $100M | Completed | Generating Revenue | ||
| 6. Debt - General | 01-Jan-2024 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series B) | 07-Mar-2022 | Completed | Generating Revenue | |||
| 4. Debt - General | 29-Nov-2018 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 07-Aug-2017 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | $5.27M | Completed | Startup | |||
| 1. Seed Round | 20-Oct-2014 | $5.27M | $5.27M | Completed | Startup |
Karius Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series BB | ||||||||
| Series AA | 4,421,354 | $0.000100 | $0.1 | $3.37 | $3.37 | 1x | $0.32 | 8.05% |
| Series SS | 380,401 | $0.000100 | $0.29 | $1.31 | $1.31 | 1x | $0.32 | 0.27% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Karius Comparisons
Industry
Financing
Details
Karius Competitors (17)
One of Karius’s 17 competitors is Biocept, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biocept | Formerly VC-backed | San Diego, CA | ||||
| Menarini Silicon Biosystems | Formerly VC-backed | Castel Maggiore, Italy | ||||
| CosmosID | Formerly VC-backed | Germantown, MD | ||||
| Qiagen | Formerly VC-backed | Hilden, Germany | ||||
| Guardant Health | Formerly VC-backed | Palo Alto, CA |
Karius Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Karius Patents
Karius Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240301518-A1 | Microbial biomarkers in transplantation and related methods | Pending | 28-Feb-2023 | ||
| CA-3207956-A1 | Metagenomic next-generation sequencing of microbial cell-free nucleic acids in subjects with lyme disease | Pending | 12-Feb-2021 | ||
| EP-4291683-A1 | Metagenomic next-generation sequencing of microbial cell-free nucleic acids in subjects with lyme disease | Pending | 12-Feb-2021 | ||
| US-20240200151-A1 | Metagenomic next-generation sequencing of microbial cell-free nucleic acids in subjects with lyme disease | Pending | 12-Feb-2021 | ||
| EP-4291683-A4 | Metagenomic next-generation sequencing of microbial cell-free nucleic acids in subjects with lyme disease | Pending | 12-Feb-2021 | C12Q1/689 |
Karius Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Karius Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 5AM Ventures | Venture Capital | Minority | ||
| Blue Water Life Science Fund | Venture Capital | Minority | ||
| Gilde Healthcare | Venture Capital | Minority | ||
| Seventure Partners | Venture Capital | Minority | ||
| Waycross Ventures | Venture Capital | Minority |
Karius FAQs
-
When was Karius founded?
Karius was founded in 2014.
-
Where is Karius headquartered?
Karius is headquartered in Redwood City, CA.
-
What is the size of Karius?
Karius has 199 total employees.
-
What industry is Karius in?
Karius’s primary industry is Biotechnology.
-
Is Karius a private or public company?
Karius is a Private company.
-
What is the current valuation of Karius?
The current valuation of Karius is .
-
What is Karius’s current revenue?
The current revenue for Karius is .
-
How much funding has Karius raised over time?
Karius has raised $409M.
-
Who are Karius’s investors?
5AM Ventures, Blue Water Life Science Fund, Gilde Healthcare, Seventure Partners, and Waycross Ventures are 5 of 20 investors who have invested in Karius.
-
Who are Karius’s competitors?
Biocept, Menarini Silicon Biosystems, CosmosID, Qiagen, and Guardant Health are some of the 17 competitors of Karius.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
